TCGA-21-1072-01A-01R-0692-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 75
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.600
- E2F_TARGETS+0.560
- G2M_CHECKPOINT+0.540
- MTORC1_SIGNALING+0.490
- PROTEIN_SECRETION+0.440
- UNFOLDED_PROTEIN_RESPONSE+0.430
- MYC_TARGETS_V2+0.410
- ANDROGEN_RESPONSE+0.320
- OXIDATIVE_PHOSPHORYLATION+0.250
- GLYCOLYSIS+0.210
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.400
- ALLOGRAFT_REJECTION-0.350
- COAGULATION-0.350
- INTERFERON_GAMMA_RESPONSE-0.340
- IL6_JAK_STAT3_SIGNALING-0.300
- MYOGENESIS-0.280
- KRAS_SIGNALING_UP-0.200
- COMPLEMENT-0.190
- KRAS_SIGNALING_DN-0.180
- INFLAMMATORY_RESPONSE-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-33-4586-01A-01R-1443-07 | — | cohortSQ2 | 0.909 |
| 2 | MDT-AP-2956 | Med | Medulloblastoma | 0.897 |
| 3 | SRR4195653 | — | — | 0.895 |
| 4 | SRR6013564 | — | cohortSQ2 | 0.891 |
| 5 | SRR25043616 | — | — | 0.889 |
| 6 | TCGA-BT-A20N-01A-11R-A14Y-07 | — | — | 0.879 |
| 7 | TCGA-98-A538-01A-11R-A262-07 | — | cohortSQ1 | 0.879 |
| 8 | C3L-00081 | — | cohortSQ2 | 0.878 |
| 9 | MNG1011 | — | — | 0.873 |
| 10 | TCGA-66-2792-01A-01R-0980-07 | — | cohortSQ2 | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.540 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.490 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.440 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.430 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.120 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.110 | Inavolisib | — uncovered |